A decreased CD4+/CD8+ ratio is commonly associated with poor prognosis in cervical cancer, with studies showing that patients with CSCC who have a low CD4+/CD8+ ratio exhibit worse five-year survival rates (56–58), higher lymph node metastasis rates and faster tumor growth (59, 60). Here, CD4 is linked to neoplasm.